FDA Approves Pierre Fabre's Navelbine

NAVELBINE is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC). In patients with Stage IV NSCLC, NAVELBINE is indicated as a single agent or in combination with cisplatin. In Stage III NSCLC, NAVELBINE is indicated in combination with cisplatin.

Navelbine®, one of the most recent chemotherapy drugs available today, is from a group of drugs known as plant alkaloids. These drugs work by stopping the cancer cells from separating into two new cells, therefore blocking the growth of the cancer. Navelbine may be used in tandem with another chemotherapy drug from a different family of medications.

The most common uses for Navelbine® are in treating breast cancer and non small-cell lung cancer. Fewer side effects are noted with this drug than with any other chemotherapy drug, especially those that were developed 20 to 30 years ago.

Navelbine (also known as Vinorelbine) is relatively unique among chemotherapy drugs used for the treatment of mesothelioma because most chemotherapy drugs are entirely synthetic, whereas Navelbine is a semi-synthetic drug that is extracted from a flowering plant known as periwinkle.

Navelbine injection and capsules both contain the active ingredient vinorelbine, which is a chemotherapy medicine used to treat cancer. (NB Vinorelbine injection is also available without a brand name, ie as the generic medicine.)
Cancers form when some cells within the body multiply uncontrollably and abnormally. These cells spread, destroying nearby tissues. Vinorelbine works by stopping the cancer cells from multiplying.
Like normal healthy cells, cancer cells go through a continuous process of change. Each cell divides into two daughter cells. These cells grow, rest and then divide again. The medicines used in chemotherapy are powerful chemicals designed to interupt this cycle and stop cells from growing and multiplying.